Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Poll|September 5, 2018
As a physician, when choosing a new specialist to see, do you read online reviews of the provider first?
Advertisement
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5